Sangamo Therapeutics Inc logo

Sangamo Therapeutics Inc Investor Relations Material

Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in therapeutic genome editing. The company's lead program is focused on treating inherited blood disorder beta-thalassemia and sickle cell disease by ex vivo genome editing in hematopoietic stem and progenitor cells from adult patients. It is also focusing on genome editing for HIV/AIDS; hemophilia; Huntington's disease; LCA6; other rare and infectious diseases; cancer and degenerative conditions. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California

Latest company events

Ticker symbol



United States of America

About the company

Investor Relations Page

Dig deeper into the Sangamo Therapeutics Inc fundamentals on Quartr.

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
App store link
Android play link
Quartr app screenshot